3(S)-(2-Methylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3(S)-(2-Methylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid
• 英文别名: 3-(2-methyl-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)-nonanoic acid；3-(2-Methylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid
• 化学式: C₂₂H₃₀N₄O₂
• 分子量: 382.506
• InChiKey: NJDBZBVQIMZWPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  28
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  88
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Alpha V integrin receptor antagonists
  申请人：——

  公开号：US20020040030A1

  公开（公告）日：2002-04-04

  The present invention relates to novel compounds formed by metabolic conversion of compounds of the structural formula depicted below (R═H or Me), pharmaceutical compositions containing such compounds, and their use as &agr;v&bgr;3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting bone resorption and for the treatment and prevention of osteoporosis. 1

  本发明涉及通过代谢转化形成的新化合物，其结构式如下所示（R═H或Me），包含此类化合物的药物组合物，以及它们作为αvβ3整合素受体拮抗剂的用途。本发明的化合物对抑制骨吸收、再狭窄、血管生成、糖尿病视网膜病变、黄斑变性、炎症性关节炎、癌症和转移性肿瘤生长具有用处。它们特别适用于抑制骨吸收以及治疗和预防骨质疏松症。
• Integrin receptor antagonists
  申请人：——

  公开号：US20020010176A1

  公开（公告）日：2002-01-24

  The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3, &agr;v&bgr;5, and/or &agr;v&bgr;6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

  本发明涉及化合物及其衍生物，其合成以及它们作为整合素受体拮抗剂的用途。更具体地说，本发明的化合物是整合素受体αvβ3、αvβ5和/或αvβ6的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松症，抑制血管再狭窄，糖尿病视网膜病变，黄斑变性，血管生成，动脉粥样硬化，炎症，伤口愈合，病毒性疾病，肿瘤生长和转移。
• Amine salts of an integrin receptor antagonist
  申请人：——

  公开号：US20020065291A1

  公开（公告）日：2002-05-30

  Amine salts of 3-(2-methyl-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]-naphthyridin-2-yl)-nonanoic acid are potent antagonists of the integrin &agr;v&bgr;3 receptor and are useful for the prevention and/or treatment of osteoporosis and vascular restenosis, as well as conditions associated with excessive angiogenesis, such as macular degeneration, diabetic retinopathy, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth. The invention also relates to a process for the preparation of the novel salts as well as pharmaceutical compositions containing the salts and methods of using the salts. Also disclosed are 3(R)- and 3(S)-(2-methylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid in the form of a zwitterion trihydrate.

  3-(2-甲基嘧啶-5-基)-9-(5,6,7,8-四氢-[1,8]-萘啶-2-基)-壬酸的胺盐是整合素&agr;v&bgr；3受体的强效拮抗剂，可用于预防和/或治疗骨质疏松症和血管再狭窄，以及与过度血管生成有关的疾病，如黄斑变性、糖尿病视网膜病变、动脉粥样硬化、炎性关节炎、癌症和转移性肿瘤生长。本发明还涉及新型盐类的制备工艺以及含有这些盐类的药物组合物和使用这些盐类的方法。本发明还公开了3(R)-和3(S)-(2-甲基嘧啶-5-基)-9-(5,6,7,8-四氢-[1,8]萘啶-2-基)-壬酸的三水齐聚物形式。
• Enantioselective bioreduction for the preparation of integrin receptor antagonist intermediates
  申请人：——

  公开号：US20020187988A1

  公开（公告）日：2002-12-12

  The present invention relates to a novel enantioselective bioreduction using a yeast microorganism for the preparation of the chiral allylic alcohols of structural formula I (R is hydrogen or methyl) which are useful in the asymmetric synthesis of integrin &agr;v&bgr;3 receptor antagonists. 1

  本发明涉及一种利用酵母微生物制备结构式 I 手性烯丙基醇（R 为氢或甲基）的新型对映体选择性生物还原方法，该方法可用于不对称合成整合素&agr;v&bgr;3 受体拮抗剂。 1
• Methods and compositions for treating peridontal disease
  申请人：——

  公开号：US20040053968A1

  公开（公告）日：2004-03-18

  The present invention provides for a method for the treatment of alveolar bone loss due to periodontal disease in a subject in need of such treatment comprising administration of a therapeutically effective amount of an &agr;v&bgr;3 integrin receptor antagonist in combination with a therapeutically effective amount of a COX-2 inhibitor. Further, the present invention provides for pharmaceutical compositions useful in the methods of the present invention, as well as a method of manufacture of a medicament useful for treating the alveolar bone loss due to periodontal disease.

  本发明提供了一种治疗需要这种治疗的受试者因牙周病引起的牙槽骨缺损的方法，该方法包括施用治疗有效量的&agr;v&bgr;3整合素受体拮抗剂与治疗有效量的COX-2抑制剂。此外，本发明还提供了在本发明方法中有用的药物组合物，以及一种用于治疗牙周病引起的牙槽骨丧失的药物的制造方法。